- New
-
Topics
- All Categories
- Metaphysics and Epistemology
- Value Theory
- Science, Logic, and Mathematics
- Science, Logic, and Mathematics
- Logic and Philosophy of Logic
- Philosophy of Biology
- Philosophy of Cognitive Science
- Philosophy of Computing and Information
- Philosophy of Mathematics
- Philosophy of Physical Science
- Philosophy of Social Science
- Philosophy of Probability
- General Philosophy of Science
- Philosophy of Science, Misc
- History of Western Philosophy
- Philosophical Traditions
- Philosophy, Misc
- Other Academic Areas
- Journals
- Submit material
- More
An Ethical Argument for Ending Human Trials of Amyloid-Lowering Therapies in Alzheimer’s Disease
American Journal of Bioethics Neuroscience 15 (2):80-81 (2024)
Abstract
Given the past two decades of over 40 failed trials of amyloid-lowering therapies in Alzheimer’s Disease (AD), many of which succeeded in lowering amyloid as designed, we present an ethical argument for emptying the drug pipeline of tests of amyloid-lowering agents so as to end the historical dominance of the amyloid-reducing therapeutic approach in AD.My notes
Similar books and articles
The experimental Alzheimer's disease drug posiphen [-phenserine] lowers amyloid-beta peptide levels in cell culture and mice.D. K. Lahiri, D. Chen, B. Maloney, H. W. Holloway, Q. S. Yu, T. Utsuki, T. Giordano, K. Sambamurti & N. H. Greig - 2007 - J Pharmacol Exp Ther 320:386-96.
Transcriptional regulation of APP by apoE: To boldly go where no isoform has gone before.Liying Corinne Lee, Michele Q. L. Goh & Edward H. Koo - 2017 - Bioessays 39 (9):1700062.
Alzheimer's in 3D culture: Challenges and perspectives.Carla D'Avanzo, Jenna Aronson, Young Hye Kim, Se Hoon Choi, Rudolph E. Tanzi & Doo Yeon Kim - 2015 - Bioessays 37 (10):1139-1148.
Stakeholders’ Views on Early Diagnosis for Alzheimer’s Disease, Clinical Trial Participation and Amyloid PET Disclosure: A Focus Group Study.Gwendolien Vanderschaeghe, Rik Vandenberghe & Kris Dierickx - 2019 - Journal of Bioethical Inquiry 16 (1):45-59.
Alzheimer’s disease : epistemology, ethics, innovation.Timothy Daly - 2021 - Dissertation, Sorbonne Université
The emerging role of cystatins in Alzheimer's disease.Eva Žerovnik - 2009 - Bioessays 31 (6):597-599.
Golgi defects enhance APP amyloidogenic processing in Alzheimer's disease.Gunjan Joshi & Yanzhuang Wang - 2015 - Bioessays 37 (3):240-247.
Copper depletion down-regulates expression of the Alzheimer's disease amyloid-beta precursor protein gene.S. A. Bellingham, D. K. Lahiri, B. Maloney, S. La Fontaine, G. Multhaup & J. Camakaris - 2004 - J Biol Chem 279:20378-86.
β-Amyloid Plaque Reduction in the Hippocampus After Focused Ultrasound-Induced Blood–Brain Barrier Opening in Alzheimer’s Disease.Pierre-François D’Haese, Manish Ranjan, Alexander Song, Marc W. Haut, Jeffrey Carpenter, Gerard Dieb, Umer Najib, Peng Wang, Rashi I. Mehta, J. Levi Chazen, Sally Hodder, Daniel Claassen, Michael Kaplitt & Ali R. Rezai - 2020 - Frontiers in Human Neuroscience 14.
Analytics
Added to PP
2022-10-07
Downloads
15 (#244,896)
6 months
27 (#573,316)
2022-10-07
Downloads
15 (#244,896)
6 months
27 (#573,316)
Historical graph of downloads
Citations of this work
Dementia Prevention Guidelines Should Explicitly Mention Deprivation.Timothy Daly - 2024 - American Journal of Bioethics Neuroscience 15 (1):73-76.
References found in this work
The Accelerated Approval of Aducanumab Invites a Rethink of the Current Model of Drug Development for Alzheimer's Disease.Timothy Daly & Stéphane Epelbaum - 2023 - American Journal of Bioethics Neuroscience 14 (3):332-335.
PhilPapers logo by Andrea Andrews and Meghan Driscoll.
This site uses cookies and Google Analytics (see our terms & conditions for details regarding the privacy implications). Use of this site is subject to terms & conditions.
All rights reserved by The PhilPapers Foundation
Server: philpapers-web-68866f4b87-zhzfn uwo